Analysts Bullish on Eli Lilly's Prospects

Firm's stock price target set at over $1,200 per share

Apr. 1, 2026 at 11:20am

Got story updates? Submit your updates here. ›

Wall Street analysts have issued a 'Moderate Buy' rating on pharmaceutical giant Eli Lilly and Company (NYSE: LLY), with a consensus price target of $1,221.44 per share. The company's stock has seen strong performance in recent quarters, driven by the success of its diverse drug portfolio and pipeline.

Why it matters

Eli Lilly is one of the world's largest and most influential pharmaceutical firms, with a market capitalization exceeding $850 billion. The company's financial performance and product development are closely watched by investors, as they can have significant implications for the broader healthcare sector.

The details

Analysts at 30 different firms have weighed in on Eli Lilly's stock, with the majority (25) issuing 'Buy' or 'Strong Buy' recommendations. Only one firm has a 'Sell' rating, while four have 'Hold' ratings. The average 12-month price target of $1,221.44 represents potential upside of over 30% from the stock's current trading level around $918. Positive factors cited by analysts include Eli Lilly's diverse drug pipeline, strong financial results, and leadership position in key therapeutic areas.

  • Eli Lilly reported Q4 2025 earnings on February 4, 2026.
  • The company has provided full-year 2026 EPS guidance in the range of $33.50 to $35.00.

The players

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

David A.

The President and Chief Executive Officer of Eli Lilly.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Eli Lilly's strong financial performance, diverse drug pipeline, and leadership position in key therapeutic areas have analysts bullish on the company's long-term prospects, with a consensus price target suggesting significant upside potential for the stock.